52 pounds lost with 1 injection per week, latest data on triple agonist Retatrutide released!

Retatrutide is a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon (GCG) triple agonist that has attracted widespread attention for its effects on significantly improving glycemic control, lipid metabolism and weight loss in patients with type 2 diabetes.

1. Results of a phase 2 clinical trial of Retatrutide in obese patients

On June 26, at the 83rd American Diabetes Association (ADA) meeting, Real Doll Professor Ania Jastreboff of Yale University School of Medicine presented the results of a Phase 2 clinical trial of Retatrutide in obese patients.

In this phase 2, double-blind, randomized controlled trial, subjects were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive weekly subcutaneous injections of Retatrutide at different doses [ 1 mg, 4 mg (initial dose, 2 mg), 4 mg (initial dose, 4 mg), 8 mg (initial dose, 2 mg), 8 mg (initial dose, 4 mg) , 12 mg (initial dose, 2 mg)] or placebo groups for 48 weeks. The primary observed endpoint was weight change at week 24 (%)

A total of 338 subjects, 51.8% male, with a mean weight of 107.7 kg and a mean body mass index (BMI) of 37.3 kg/m2, Mini Sex Doll were enrolled in the study, and the Retatrutide group showed better weight loss at all dose levels compared to the placebo group:

At 24 weeks, the mean weight changes in the Retatrutide group were -7.2% in the 1 mg group, -12.9% in the 4 mg group, -17.3% in the 8 mg group, and -17.5% in the 12 mg group;

At 48 weeks, the mean weight changes in the Retatrutide group were -8.7% in the 1 mg group, -17.1% in the 4 mg group, -22.8% in the 8 mg group, and -24.2% in the 12 mg group.

At 48 weeks, the percentages of weight loss ≥ 5%, ≥ 10% and ≥ 15% were 92%, 75% and 60% in the 4 mg group, 100%, 91% and 75% in the 8 mg group and 100%, 93% and 83% in the 12 mg group, respectively.

The most common adverse event in the retatrutide group was a mild to moderate gastrointestinal reaction, which was dose dependent. In summary, Starpery Doll Retatrutide showed good weight loss and was well tolerated in adult obese patients.

The results of the study were published online on the same day in NEJM, which also wrote in its tweet, "The magnitude of weight loss is very large compared to other weight loss drugs and is comparable to weight loss surgery.

2. Phase 2 clinical trial results of Retatrutide in a subgroup of obese NAFLD patients Milf Sexpuppe

Then, Professor Arun Sanyal of Virginia Commonwealth University School of Medicine shared the latest results of a phase 2 clinical trial of Retatrutide in a subgroup of patients with non-alcoholic fatty liver disease (NAFLD) during the ADA symposium.

ralph lauren polo Study Background

Non-alcoholic steatohepatitis (NASH) is a progressive stage of NAFLD characterized by steatosis, inflammation and hepatocellular injury with or without fibrosis [1]. However, no therapeutic agents for NASH have been marketed and approved.

Enterostatin-based treatments, including glucagon-like peptide-1 (GLP -1) and glucose-dependent glucagon releasing polypeptide (GlP) receptor agonists, have been shown to reduce liver fat and improve NASH-related biomarkers in patients with NAFLD [2-5]. For example, Anime Sex Doll the results of a phase 2 clinical study of semaglutide with liver tissue biopsies demonstrated histological improvement of NASH after semaglutide treatment [5].

The results of a growing number of studies confirm that GIP/GLP-1/glucagon (GCG) triple agonists are effective in reducing liver fat in patients with NAFLD [6].